BACKGROUND: Studies focusing on short- and mid-term follow up support the beneficial role of sirolimus-eluting stents (SES) in the treatment of in-stent restenosis (ISR), yet no long-term safety and/or efficacy data are available. METHODS: Patients with ISR following bare-metal stenting (BMS) and treated with SES were prospectively studied. Baseline, procedural, and in-hospital data were appraised. The primary endpoint was the rate of major cardiovascular events (MACE) at long-term follow up (>9 months). Secondary endpoints were the individual contributors to MACE. RESULTS: A total of 180 SES were implanted to treat 138 consecutive patients. Procedural success was achieved in all patients without in-hospital death, acute stent thrombosis, stroke, or urgent coronary artery bypass. During follow up, MACE occurred in 5.8% of patients at 6 months, 14.3% at 12 months, and 25% at 24 months. Specifically, all-cause mortality was 1.7% at 6 months, 3.5% at 12 months, and 4.8% at 24 months, for a total of 5 deaths. Target vessel revascularization occurred at 6, 12, and 24 months in 4.2%, 11.2%, and 15.9% of patients, respectively, while target lesion revascularization (TLR) alone accounted for 3.4% at 6 months, 9.6% at 12 months, and 11% at 24 months. Three case of myocardial infarction occurred during follow up (2.2%), without any surgical revascularization or stent thrombosis. CONCLUSIONS: Treatment of ISR with SES appears safe and effective, even if a 10% annual rate of MACE can be expected, with a sizable portion of these due to apparently nontarget lesion events. © 2007 HMP Communications | All Rights Reserved.

Sirolimus-eluting stents for the treatment of bare-metal in-stent restenosis: Long-term clinical follow up / I., Sheiban; A., Chiribiri; S., Beninati; C., Moretti; P., Omede; F., Sciuto; W. G., Marra; BIONDI ZOCCAI, Giuseppe; M., Bollati; A., Gambino; G. P., Trevi. - In: JOURNAL OF INVASIVE CARDIOLOGY. - ISSN 1042-3931. - 19:4(2007), pp. 174-180.

Sirolimus-eluting stents for the treatment of bare-metal in-stent restenosis: Long-term clinical follow up

BIONDI ZOCCAI, GIUSEPPE;
2007

Abstract

BACKGROUND: Studies focusing on short- and mid-term follow up support the beneficial role of sirolimus-eluting stents (SES) in the treatment of in-stent restenosis (ISR), yet no long-term safety and/or efficacy data are available. METHODS: Patients with ISR following bare-metal stenting (BMS) and treated with SES were prospectively studied. Baseline, procedural, and in-hospital data were appraised. The primary endpoint was the rate of major cardiovascular events (MACE) at long-term follow up (>9 months). Secondary endpoints were the individual contributors to MACE. RESULTS: A total of 180 SES were implanted to treat 138 consecutive patients. Procedural success was achieved in all patients without in-hospital death, acute stent thrombosis, stroke, or urgent coronary artery bypass. During follow up, MACE occurred in 5.8% of patients at 6 months, 14.3% at 12 months, and 25% at 24 months. Specifically, all-cause mortality was 1.7% at 6 months, 3.5% at 12 months, and 4.8% at 24 months, for a total of 5 deaths. Target vessel revascularization occurred at 6, 12, and 24 months in 4.2%, 11.2%, and 15.9% of patients, respectively, while target lesion revascularization (TLR) alone accounted for 3.4% at 6 months, 9.6% at 12 months, and 11% at 24 months. Three case of myocardial infarction occurred during follow up (2.2%), without any surgical revascularization or stent thrombosis. CONCLUSIONS: Treatment of ISR with SES appears safe and effective, even if a 10% annual rate of MACE can be expected, with a sizable portion of these due to apparently nontarget lesion events. © 2007 HMP Communications | All Rights Reserved.
2007
01 Pubblicazione su rivista::01a Articolo in rivista
Sirolimus-eluting stents for the treatment of bare-metal in-stent restenosis: Long-term clinical follow up / I., Sheiban; A., Chiribiri; S., Beninati; C., Moretti; P., Omede; F., Sciuto; W. G., Marra; BIONDI ZOCCAI, Giuseppe; M., Bollati; A., Gambino; G. P., Trevi. - In: JOURNAL OF INVASIVE CARDIOLOGY. - ISSN 1042-3931. - 19:4(2007), pp. 174-180.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/433987
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact